SLC5A2 and type 2 diabetes mellitus: The clinical trials involving SGLT2-is have significantly improved cardiac outcomes in T2DM patients and they seem to show a class effect, with empagliflozin being the first glucose-lowering agent that significantly reduces HF, mortality, hospitalization and renal disease progression in diabetic patients (Figure 3).